Teva launches generic AndroGelTestosterone gel 1.62% had an annual market value of more than $911 million, according to February 2019 IQVIA data. Lupin gets FDA green light for generic ProzacFluoxetine tablets had an annual market value of roughly $68.2 million, according to December 2018 IQVIA data. ANI Pharmaceuticals deal boosts injectable portfolio ANI Pharmaceuticals has added a second specialty injectable product to its pipeline, the first product being Cortrophin gel. Dr. Reddy's to acquire generic injectables portfolio Dr. Reddy's is set to 42 products with a market value of roughly $645 million. Zydus Cadila’s generic Xeljanz gets tentative approval Zydus Cadila's generic Xeljanz tablets are used to treat moderate to severe forms of rheumatoid arthritis. Sandoz resubmits Neulasta biosimilar application to FDA Sandoz's biosimilar of Neulasta, pegfilgrastim, is a long-acting version of filgrastim for cancer patients. FDA gives tentative nod to Zydus Cadila’s generic Vimpat Lacosamide is an anticonvulsant drug used to prevent and control seizures. Amneal appoints new chief scientific officer Pradeep Bhadauria has more than two decades of generic and specialty pharmaceutical experience. Lupin names independent director Christine Mundkur has held leadership roles at Impopharma, Sandoz, and Barr. Sandoz launches generic Remodulin Sandoz will collaborate with RareGen to commercialize its generic Remodulin (treprostinil injection). First Previous 192 193 194 195 196 Next Last
